Clinicopathologic features and tumor immune microenvironment of lymphocyte-rich hepatocellular carcinoma

Yi-Wang Zhang,Chang Zhao,Bo-Jing Su,Wei-Zheng Lin,Wei-Min Liu,Jing Liang,Chun-Kui Shao,Na Cheng,Jian-Ning Chen
DOI: https://doi.org/10.1016/j.anndiagpath.2024.152382
IF: 2.134
2024-10-12
Annals of Diagnostic Pathology
Abstract:Lymphocyte-rich hepatocellular carcinoma (LR-HCC) is a rare variant of HCC characterized by pronounced lymphoid infiltration, providing an opportunity to explore the tumor immune microenvironment (TIME) and its potential impact on disease progression and therapy. This study aimed to describe the clinicopathological features and TIME components of LR-HCC to inform more effective treatment strategies. In this study, we present five novel cases of LR-HCC alongside a comprehensive retrospective analysis of 136 previously documented cases. Immunohistochemical evaluation was utilized to systematically assess TIME components and immune checkpoint inhibitor (ICI) targets. Our findings demonstrated a significant predominance of CD3+ T cells over CD20+ B cells (1.5:1, P < 0.001) and a higher frequency of CD8+ cytotoxic T cells compared to Foxp3+ regulatory T cells (2.4:1, P 90 %), with 29.4 % of patients experiencing postoperative recurrence or lymph node metastasis. Multivariate analysis identified tumor size as an independent predictor of overall survival. These findings emphasize the relevance of TIME characteristics in understanding LR-HCC and point to promising avenues for targeted and immune-based therapies, contributing to the optimization of clinical management for this distinct cancer subtype.
pathology
What problem does this paper attempt to address?